The cannabinoid CB2 receptor is a peripheral receptor found predominantly in the immune system and regulates inflammation and the immune response. Elevated CB2 receptor expression is associated with worse overall patient survival and aggressiveness of cancer.
Our novel, small molecule, TT-816, is a cannabinoid CB2 receptor antagonist acting as an immune checkpoint inhibitor for the treatment of a broad range of solid tumors. It shows the ability to enhance innate and adaptive immunity; synergize anti-tumor effect with current immune checkpoint inhibitors and directly promote immune cell penetration into solid tumors.
The FDA accepted the Investigational New Drug (IND) application for the study of TT-816 and is now available as a clinical trial.
Compelling Pre-Clinical Data Supporting TT-816
TT-816 Is Superior to Anti-PD-1 and Synergizes Anti-PD-1 Efficacy
TT-816 enhances the effect of anti-PD-1 in the hot tumor model
TT-816 is superior to anti-PD-1 in cold tumor model and combination with anti-PD-1 synergistically inhibits cold tumor growth
TT-816 Increases T and NK Cell Infiltration and Reduces Myeloid-derived Suppressor Cells (MDSCs)
TT-816 facilitates infiltration of CD4+ and CD8+ T cells, NK cells and reduces MDSCs
TT-816 enhances the effect of anti-PD-1 on T cell and NK cell infiltration
Teon’s rich pipeline targets unexploited metabolic pathways backed by well-validated science and a track record developing first- and best-in-class GPCR-directed therapies.